These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16391300)

  • 21. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
    J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Safety of pemetrexed according to the duration of vitamin B12 and folic acid supplementation prior to the first dose of pemetrexed].
    Tsuda Y; Kitamura A; Nishimura N; Yagi N; Takayama S; Okafuji K; Tomishima Y; Jinta T; Koyama K; Ohde S; Gotoh K; Chohnabayashi N
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):471-5. PubMed ID: 25963695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
    Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.
    McDonald AC; Vasey PA; Adams L; Walling J; Woodworth JR; Abrahams T; McCarthy S; Bailey NP; Siddiqui N; Lind MJ; Calvert AH; Twelves CJ; Cassidy J; Kaye SB
    Clin Cancer Res; 1998 Mar; 4(3):605-10. PubMed ID: 9533527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
    Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK
    J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
    Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P
    Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
    Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
    Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
    Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
    Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
    Ellis PM; Chu QS; Leighl N; Laurie SA; Fritsch H; Gaschler-Markefski B; Gyorffy S; Munzert G
    Clin Lung Cancer; 2013 Jan; 14(1):19-27. PubMed ID: 22658814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
    Pivot X; Raymond E; Laguerre B; Degardin M; Cals L; Armand JP; Lefebvre JL; Gedouin D; Ripoche V; Kayitalire L; Niyikiza C; Johnson R; Latz J; Schneider M
    Br J Cancer; 2001 Sep; 85(5):649-55. PubMed ID: 11531245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer.
    Paridaens R; Dirix L; Dumez H; Prové A; Wildiers H; Alvarez A; Oliveira CT; Latz J; Simms L; Melemed A
    Clin Breast Cancer; 2007 Dec; 7(11):861-6. PubMed ID: 18269776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature.
    Brandes JC; Grossman SA; Ahmad H
    Cancer Invest; 2006; 24(3):283-7. PubMed ID: 16809156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs.
    Hendricksen K; Moonen PM; van der Heijden AG; Molkenboer-Kuenen J; Hulsbergen-van de Kaa CA; Witjes JA
    Clin Cancer Res; 2006 Apr; 12(8):2597-601. PubMed ID: 16638871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
    O'Shaughnessy JA; Clark RS; Blum JL; Mennel RG; Snyder D; Ye Z; Liepa AM; Melemed AS; Yardley DA
    Clin Breast Cancer; 2005 Jun; 6(2):143-9. PubMed ID: 16001992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.
    Alberts SR; Kim GP; Mahoney MR; Gornet MK; Rubin J; Ames M; Goetz MP; Weinshilboum RM; Nicol SJ; Goldberg RM
    Clin Colorectal Cancer; 2007 Jul; 6(8):572-7. PubMed ID: 17681103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
    Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.